Public stakeholder meeting: approval, safety monitoring and impact of COVID-19 vaccines in the EU
Table of contents
Date:
26/03/2021
Location:
Virtual meeting, 13:00 - 15:15 (CET)
This third public meeting updated EU citizens about the continued assessment, approval and safety monitoring of COVID-19 vaccines, and their expected impact at community level.
It covered:
- COVID-19 vaccines approved in the EU and those currently under review;
- post-authorisation activities, including emerging safety data since EU authorisation of the first COVID-19 vaccines;
- ongoing work to address new variants;
- the expected impact of COVID-19 vaccination on our society;
- transparency and the publication of clinical data for COVID-19 vaccines.
The event also allowed the public and stakeholders to further inform EMA of their needs, expectations and any concerns.
Full video recording
Update on approved and candidate COVID-19 vaccines in the EU, Marco Cavaleri (EMA)
Vaccines safety monitoring – update on emerging data since EU authorisations, Peter Arlett (EMA)
Expected impact of COVID-19 vaccination in the European Union, Edoardo Colzani (ECDC)
Transparency and publication of clinical data for COVID-19 vaccines, Melanie Carr (EMA)
-
List item
Agenda - Public stakeholder meeting: approval, safety monitoring and impact of COVID-19 vaccines in the EU (PDF/302.37 KB)
First published: 22/02/2021
Last updated: 24/03/2021 -
List item
Presentation - Update on approved and candidate COVID-19 vaccines in the EU (M.Cavaleri, EMA) (PDF/651.05 KB)
First published: 29/03/2021 -
List item
Presentation - COVID-19 vaccines safety monitoring (P.Arlett, EMA) (PDF/456.65 KB)
First published: 29/03/2021 -
List item
Presentation - Expected impact of COVID-19 vaccination in the European Union (E.Colzani, ECDC) (PDF/943.5 KB)
First published: 29/03/2021 -
List item
Presentation - Transparency and publication of clinical data for COVID-19 vaccines (M.Carr, EMA) (PDF/2.84 MB)
First published: 29/03/2021